675 related articles for article (PubMed ID: 29478344)
1. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
[TBL] [Abstract][Full Text] [Related]
2. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
3. A safety evaluation of guselkumab for the treatment of psoriasis.
Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
Expert Opin Drug Saf; 2018 Jul; 17(7):741-751. PubMed ID: 29897790
[TBL] [Abstract][Full Text] [Related]
4. A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
Nawas Z; Hatch M; Ramos E; Liu M; Tong Y; Peranteau A; Tyring S
Skin Therapy Lett; 2017 Mar; 22(2):8-10. PubMed ID: 28329405
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
6. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
Nemoto O; Hirose K; Shibata S; Li K; Kubo H
Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
[TBL] [Abstract][Full Text] [Related]
8. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
Al-Salama ZT; Scott LJ
Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
[TBL] [Abstract][Full Text] [Related]
12. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
14. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
[TBL] [Abstract][Full Text] [Related]
16. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
18. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
Frampton JE
Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
[TBL] [Abstract][Full Text] [Related]
19. Guselkumab: First Global Approval.
Markham A
Drugs; 2017 Sep; 77(13):1487-1492. PubMed ID: 28819723
[TBL] [Abstract][Full Text] [Related]
20. Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis.
Yang EJ; Smith MP; Ly K; Bhutani T
Drug Des Devel Ther; 2019; 13():1993-2000. PubMed ID: 31354244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
